Search

Your search keyword '"Salzer, Helmut J. F."' showing total 249 results

Search Constraints

Start Over You searched for: Author "Salzer, Helmut J. F." Remove constraint Author: "Salzer, Helmut J. F."
249 results on '"Salzer, Helmut J. F."'

Search Results

1. Key summary of German national guideline for adult patients with nosocomial pneumonia- Update 2024 Funding number at the Federal Joint Committee (G-BA): 01VSF22007

4. European Network for ICU-Related Respiratory Infections (ENIRRIs): a multinational, prospective, cohort study of nosocomial LRTI

7. Consensus Statement der Österreichischen Gesellschaften für Rheumatologie und Rehabilitation, Pneumologie, Infektiologie, Dermatologie und Gastroenterologie zum Umgang mit latenter Tuberkulose bei Therapien mit biologischen oder „targeted synthetic“ DMARDs („disease modifying antirheumatic drugs“)

8. National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs)

12. Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022): Updated statement of the Austrian Society of Pneumology (ASP)

13. EQUAL ABPA Score 2024: A Tool to Measure Guideline Adherence for Managing Allergic Bronchopulmonary Aspergillosis.

16. Virus-induced senescence is a driver and therapeutic target in COVID-19

21. The Austrian landscape of diagnostic capacity and access to treatment for invasive fungal infections

23. Therapie bei MDR-, prä-XDR-, XDR-Tuberkulose und Rifampicin-Resistenz oder bei Medikamentenunverträglichkeit gegenüber mindestens Rifampicin *.

24. Tuberculosis incidence in foreign-born people residing in European countries in 2020

26. Elevated Levels of Interleukin 17A and Kynurenine in Candidemic Patients, Compared With Levels in Noncandidemic Patients in the Intensive Care Unit and Those in Healthy Controls

27. Consensus Statement der Österreichischen Gesellschaften für Rheumatologie und Rehabilitation, Pneumologie, Infektiologie, Dermatologie und Gastroenterologie zum Umgang mit latenter Tuberkulose bei Therapien mit biologischen oder „targeted synthetic“ DMARDs („disease modifying antirheumatic drugs“)

28. Antiinfektive Therapie von Pilzinfektionen durch Candidaund Aspergillus

30. Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement

34. A Model Predicting Mortality of Hospitalized Covid-19 Patients Four Days After Admission: Development, Internal and Temporal-External Validation

35. Processing Hundreds of SARS-CoV-2 Samples with an In-House PCR-Based Method without Robotics

36. Rare manifestation of a large stenosing gastrointestinal tumor caused by Mycobacterium tuberculosis in a previously healthy man from Austria

37. Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study

39. qSOFA score poorly predicts critical progression in COVID-19 patients

40. Viruses / Processing hundreds of SARS-CoV-2 samples with an in-house PCR-based method without robotics

41. Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model

44. CPAnet Registry-An International Chronic Pulmonary Aspergillosis Registry

45. Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke:The Global COVID-19 Stroke Registry

Catalog

Books, media, physical & digital resources